<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574598</url>
  </required_header>
  <id_info>
    <org_study_id>INCAN/014/033/ICI</org_study_id>
    <secondary_id>INCAN/014/033/ICI</secondary_id>
    <nct_id>NCT02574598</nct_id>
  </id_info>
  <brief_title>MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients</brief_title>
  <official_title>A Randomized Crossover, Phase II Clinical Trial of MK-3475 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Treated.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label randomized clinical trial of MK-3475 (Pembrolizumab) on&#xD;
      previously treated non-small cell lung cancer (NSCLC) patients . This drug has shown to allow&#xD;
      partial response according to the immune-related response criteria and the response&#xD;
      evaluation criteria in solid tumors (RECIST). The main endpoint is to compare the overall&#xD;
      response rate (ORR) of MK-3475 with docetaxel or docetaxel alone in patients with advanced&#xD;
      NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MK-3475 (MK-3475) is an IgG4 monoclonal antibody to PD1, which received a 'breakthrough&#xD;
      therapy' designation for advanced melanoma from the FDA in January 2013. Preliminary results&#xD;
      from the NSCLC cohort of a phase I dose expansion trial of MK-3475 were presented at the 2013&#xD;
      World Conference on Lung Cancer meeting. MK-3475 was administered intravenously every three&#xD;
      weeks, and continued until disease progression based upon immune related response criteria&#xD;
      (irRC) or unacceptable toxicity. IrRC take into account the potential for different patterns&#xD;
      of response that can be seen with immunotherapy. Of the 38 patients with previously treated&#xD;
      advanced NSCLC evaluable for efficacy, 9 (24 percent) achieved at least partial response by&#xD;
      irRC. Standard oncology criteria for response (Response Evaluation Criteria In Solid Tumors,&#xD;
      RECIST were available for 33 of these patients, with at least a partial response in seven&#xD;
      patients (21 percent). Median overall survival was 51 weeks. Therapy was well tolerated, with&#xD;
      one case of pneumonitis (grade 2) and one case of pulmonary edema (grade 3) reported. Tumor&#xD;
      PDL1 expression (assessed with a different assay than that used for the trials evaluating&#xD;
      Nivolumab and MPDL3280A; antibody used undisclosed) was available for 33 of the patients who&#xD;
      had irRC assessments and 29 of those with standard oncology (RECIST) assessment. Of the 9&#xD;
      patients with PDL1 positivity and irRC response data, 6 achieved at least partial response&#xD;
      (67 percent); of the 7 patients with PDL1 positivity and standard oncology response data, 4&#xD;
      achieved response (57 percent). Of note, 1 of 24 patients with PDL1 negativity achieved&#xD;
      response by irRC; 2 of 22 patients with PDL1 negativity had response by standard oncology&#xD;
      criteria (RECIST).&#xD;
&#xD;
      Based upon these results, a randomized phase II trial comparing MK-3475 to standard salvage&#xD;
      docetaxel in patients with advanced NSCLC has been launched (NCT01905657), however there is&#xD;
      no study in which the synergistic activity of Docetaxel + MK-3475 were evaluated, this could&#xD;
      open the possibility of using this drug concurrently with Docetaxel as standard therapy in&#xD;
      patients with progression of the disease despite a double platinum-based regimen.&#xD;
&#xD;
      Measure the expression levels of PD1/PD-L1/PD-L2 subpopulations tumor cells of patients with&#xD;
      NSCLC who come to the clinic of the National Cancer Institute and relevant way, associating&#xD;
      their role forecast and its potential as a biomarker, relating the PD-L1 levels with&#xD;
      clinicopathologic characteristics of the patients studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned (1:1) using a random numbers table to receive either monotherapy Docetaxel for 6 cycles or Pembrolizuymab plus Docetaxel for 6 cycles, following with maintenance therapy with Pembrolizumab until disease progression or unacceptable toxicity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from baseline to 2 months of treatment</time_frame>
    <description>The objective response rate (ORR) per response evaluation criteria in solit tumors (RECIST v1.1) was defined as the sum of complete response or partial response assessed by RECIST (v1.1) and is presented as the percent of participants with 95% Confidence Intervals (CI). Complete response (CR) was considered if there was a dissapearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to &lt;10 mm. Partial response (PR) was considered if there was at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Docetaxel + MK-3475</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 every 3 weeks until progression of disease&#xD;
MK-3475 (administered on day 8) 200mg every 3 until progression of disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <description>The dosing interval of pembrolizumab can be increased in case of toxicity.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_label>Docetaxel + MK-3475</arm_group_label>
    <other_name>pembrolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Use on both arms as standard of care.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_label>Docetaxel + MK-3475</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
               1. Patients should be signed and dated form of written informed consent approved by&#xD;
                  the IRB / IEC in accordance with regulatory and institutional guidelines. This&#xD;
                  must be obtained before performing any procedure related to the protocol that are&#xD;
                  not part of the normal care of the patient.&#xD;
&#xD;
               2. Patients must be willing and able to comply with scheduled visits , treatment&#xD;
                  program , laboratory testing including filling of questionnaires the results&#xD;
                  reported by the patient and other study requirements .&#xD;
&#xD;
          2. Target Population&#xD;
&#xD;
               1. Subjects with locally advanced NSCLC of squamous cell and non-squamous cell&#xD;
                  (adenocarcinoma and big cells) histological or cytologically documented , those&#xD;
                  who submit Stage IIIB / IV or recurrent disease after receiving radiation&#xD;
                  treatment or surgical resection&#xD;
&#xD;
               2. Men and women ≥ 18 years of age.&#xD;
&#xD;
               3. Performance status Eastern Cooperative Oncology Group ( ECOG ) ≤ 1.&#xD;
&#xD;
               4. Subjects must have measurable disease by CT or MRI according to RECIST 1.1&#xD;
                  criteria Radiographic Evaluation of Tumor on in the span of 28 days before&#xD;
                  randomization.&#xD;
&#xD;
               5. The target lesions may be located on a previously irradiated field exists if&#xD;
                  documented progression of disease (radiographic) in that site. Subjects&#xD;
                  progression or recurrence of the disease must have experienced during or after&#xD;
                  prior chemotherapy regimen containing platinum in metastatic disease.&#xD;
&#xD;
                  This includes individuals who meet the following criteria:&#xD;
&#xD;
                    1. Subjects who received pemetrexed, bevacizumab or erlotinib as maintenance&#xD;
                       therapy (non-progressors double platinum-based chemotherapy) and progressed&#xD;
                       are eligible However, patients who received a wild EGFR tyrosine kinase&#xD;
                       inhibitor after failure of prior platinum-based therapy were excluded.&#xD;
&#xD;
                    2. Eligible patients who received double- platinum -based chemotherapy in&#xD;
                       adjuvant or neo adjuvant (after surgery and / or radiation) and developed&#xD;
                       recurrent or metastatic disease within 6 months after treatment ends&#xD;
&#xD;
                    3. Eligible individuals with recurrent disease &gt; 6 months after adjuvant&#xD;
                       chemotherapy or neoadjuvant platinum-based , who also subsequently&#xD;
                       progressed during or after one platinum-based doublet regimen to treat&#xD;
                       recurrences&#xD;
&#xD;
                    4. Subjects with a known mutation of EGFR and received EGFR TKI (erlotinib ,&#xD;
                       gefitinib or experimental) and double platinum-based chemotherapy (&#xD;
                       regardless of the order of administration).&#xD;
&#xD;
                    5. subjects with known ALK translocation double receiving platinum-based&#xD;
                       chemotherapy and ALK inhibitor ( crizotinib or experimental )&#xD;
&#xD;
                    6. patients who have received &gt;30Gy to the chest should have waited at least 6&#xD;
                       months from completing radiation to starting pembrolizumab.&#xD;
&#xD;
               6. must be available a blood sample, for evaluation of biomarkers. Samples must be&#xD;
                  received by the central laboratory before randomization.&#xD;
&#xD;
               7. All baseline laboratory requirements will be evaluated , and must be obtained -14&#xD;
                  days of randomization. The screening laboratory values must meet the following&#xD;
                  criteria:&#xD;
&#xD;
             i) WBC ≥ 2000/μL ii) iNeutrophils ≥ 1500/μL iii) Platelets ≥ 100 x 10 ³ / uL iv)&#xD;
             Hemoglobin ≥ 9.0 g / dL v) Serum creatinine ≤ 1.5 x ULN or creatinine clearance &gt; 40&#xD;
             mL / min (using the Cockcroft / Gault ) Women : CrCl = (140 - age in years) x weight&#xD;
             in kg x 0.85 72 x serum creatinine in mg / dL Males: CrCl = (140 - age in years) x&#xD;
             weight in kg x 1.00 72 x serum creatinine in mg / dL vi) ≤ 1.5 X ULN AST vii) ≤ 1.5 X&#xD;
             ULN ALT viii) Total bilirubin ≤ 1.5x ULN (except for subjects with Gilbert 's Syndrome&#xD;
             who must have total bilirubin &lt; 3.0 mg / dL ) h ) pretreatment with radiotherapy or&#xD;
             radiosurgery at least 3 weeks must be completed before randomization.&#xD;
&#xD;
             i ) Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are stable (without evidence of progression by imaging for at least four weeks&#xD;
             prior to the first dose of trial treatment and any neurologic symptoms have returned&#xD;
             to baseline), have no evidence of new or enlarging brain metastases, and are not using&#xD;
             steroids for at least 7 days prior to trial treatment. This exception does not include&#xD;
             carcinomatous meningitis which is excluded regardless of clinical stability.&#xD;
&#xD;
          3. Age and Reproductive Status&#xD;
&#xD;
               1. Women with reproductive potential ( WOCBP ) should use contraceptive methods&#xD;
                  based on tables found in Appendix 2 . When a teratogenic drug test is used , and&#xD;
                  / or a drug for which there is not enough information to assess teratogenicity (&#xD;
                  have not been conducted preclinical studies) are required to use a highly&#xD;
                  effective method of contraception ( failure rate less than 1 % per year).&#xD;
                  Individual methods of contraception should be determined in consultation with the&#xD;
                  researcher.&#xD;
&#xD;
               2. The WOCBP must have a negative pregnancy test in serum or urine ( minimum&#xD;
                  sensitivity 25 IU / L or equivalent units of HCG ) 24 hours before starting the&#xD;
                  investigational product .&#xD;
&#xD;
               3. Women should not be breastfeeding .&#xD;
&#xD;
          4. Subjects must:&#xD;
&#xD;
               1. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
               2. Be &gt; 18 years of age on day of signing informed consent.&#xD;
&#xD;
               3. Have measurable disease based on RECIST 1.1.&#xD;
&#xD;
               4. Have provided tissue from an archival tissue sample or newly obtained core or&#xD;
                  excisional biopsy of a tumor lesion.&#xD;
&#xD;
               5. Have a performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
        6. Demonstrate adequate organ function as defined in Table 1, all screening labs should be&#xD;
        performed within 10 days of treatment initiation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must be excluded from participating in the trial if the subject:&#xD;
&#xD;
          1. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or using an investigational device within 4 weeks of the first dose of&#xD;
             treatment.&#xD;
&#xD;
          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not&#xD;
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at&#xD;
             baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          5. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy.&#xD;
&#xD;
          6. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are stable (without evidence of progression by imaging for at least four weeks&#xD;
             prior to the first dose of trial treatment and any neurologic symptoms have returned&#xD;
             to baseline), have no evidence of new or enlarging brain metastases, and are not using&#xD;
             steroids for at least 7 days prior to trial treatment.&#xD;
&#xD;
          7. Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or&#xD;
             Sjorgen's syndrome will not be excluded from the study.&#xD;
&#xD;
          8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          9. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         10. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         11. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         12. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including&#xD;
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways).&#xD;
&#xD;
         14. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         15. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar G Arrieta, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cancer of Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute of Mexico</name>
      <address>
        <city>Mexico city</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Disis ML. Immune regulation of cancer. J Clin Oncol. 2010 Oct 10;28(29):4531-8. doi: 10.1200/JCO.2009.27.2146. Epub 2010 Jun 1.</citation>
    <PMID>20516428</PMID>
  </reference>
  <reference>
    <citation>Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793-800. Epub 2002 Jun 24. Erratum in: Nat Med 2002 Sep;8(9):1039.</citation>
    <PMID>12091876</PMID>
  </reference>
  <reference>
    <citation>Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002 Feb;2(2):116-26. Review.</citation>
    <PMID>11910893</PMID>
  </reference>
  <reference>
    <citation>Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003 Feb 1;170(3):1257-66.</citation>
    <PMID>12538684</PMID>
  </reference>
  <reference>
    <citation>Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x. Review.</citation>
    <PMID>20636820</PMID>
  </reference>
  <reference>
    <citation>Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010 Apr 12;11:19. doi: 10.1186/1471-2172-11-19.</citation>
    <PMID>20385003</PMID>
  </reference>
  <reference>
    <citation>Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S, Cosmi L, Maggi L, Angeli R, Mazzinghi B, Romagnani P, Maggi E, Carini M, Romagnani S, Annunziato F. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011 May;107(9):1500-6. doi: 10.1111/j.1464-410X.2010.09555.x. Epub 2010 Aug 24.</citation>
    <PMID>20735382</PMID>
  </reference>
  <reference>
    <citation>Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother. 2010 Jun;59(6):909-19. doi: 10.1007/s00262-010-0817-1. Epub 2010 Jan 20.</citation>
    <PMID>20087581</PMID>
  </reference>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.</citation>
    <PMID>19934295</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <results_first_submitted>October 22, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2020</results_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodríguez</investigator_full_name>
    <investigator_title>Investigador en Ciencias Médicas &quot;E&quot;</investigator_title>
  </responsible_party>
  <keyword>PDL1</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Once the information recruitment is concluded ( starting 6 months after publication)</ipd_time_frame>
    <ipd_access_criteria>Only information will be given to the principal investigator, with a signed request and registration of the protocol.&#xD;
For research and statistical purposes that are required. For future statistics publications related to this study.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02574598/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel + MK-3475</title>
          <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles MK-3475 (200mg, Day 8, every 3 weeks), followed by maintenance therapy with MK-3475 until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel + MK-3475</title>
          <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles MK-3475 (200mg, Day 8, every 3 weeks), followed by maintenance therapy with MK-3475 until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="13.2"/>
                    <measurement group_id="B2" value="62.1" spread="11.6"/>
                    <measurement group_id="B3" value="60.01" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>The objective response rate (ORR) per response evaluation criteria in solit tumors (RECIST v1.1) was defined as the sum of complete response or partial response assessed by RECIST (v1.1) and is presented as the percent of participants with 95% Confidence Intervals (CI). Complete response (CR) was considered if there was a dissapearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to &lt;10 mm. Partial response (PR) was considered if there was at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
        <time_frame>from baseline to 2 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel + MK-3475</title>
            <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles MK-3475 (200mg, Day 8, every 3 weeks), followed by maintenance therapy with MK-3475 until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m2 day 1 every 3 weeks for 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>The objective response rate (ORR) per response evaluation criteria in solit tumors (RECIST v1.1) was defined as the sum of complete response or partial response assessed by RECIST (v1.1) and is presented as the percent of participants with 95% Confidence Intervals (CI). Complete response (CR) was considered if there was a dissapearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to &lt;10 mm. Partial response (PR) was considered if there was at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
          <units>percentage of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="26.9" upper_limit="58.1"/>
                    <measurement group_id="O2" value="15.8" lower_limit="4.0" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All adverse events were recorded during each clinical visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel + MK-3475</title>
          <description>Docetaxel 75 mg/m2 every 3 weeks until progression of disease&#xD;
MK-3475 (administered on day 8) 200mg every 3 until progression of disease&#xD;
MK-3475: The dosing interval of pembrolizumab can be increased in case of toxicity.&#xD;
Docetaxel: Use on both arms as standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease&#xD;
MK-3475: The dosing interval of pembrolizumab can be increased in case of toxicity.&#xD;
Docetaxel: Use on both arms as standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothiroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypothiroidism</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperthiroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sjogren</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirrubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyporexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The data here presented should be interpreted in light of its limitations. Foremost, the study was designed in the absence of recently established information, and therefore, several factors were not available during the patient selection process, including PD-L1 expression for all included patients. Additionally, patients with common oncogenic driver mutations, including EGFR could be enrolled. This generates a heterogeneous population with several already characterized subgroups present.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Oscar Arrieta</name_or_title>
      <organization>Instituto Nacional de Cancerología</organization>
      <phone>(52) 55-5628-0400 ext 71101</phone>
      <email>ogar@unam.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

